Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06369285
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-12
Brief Title:
A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive HER2-negative Recurrent or Metastatic Breast Cancer
Sponsor:
Puma Biotechnology Inc
Organization:
Puma Biotechnology Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-12
First Submit QC Date:
April 12 2024
Study First Post Date:
2024-04-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-16
Last Update Post Date:
2024-04-16
Last Update Post Date Type:
ACTUAL